What is Avitia?
Avitia is a biotechnology company focused on revolutionizing cancer mutation testing for clinical laboratories. The company develops modular and cost-effective molecular testing solutions designed to generate rapid, precise, and actionable insights. By empowering labs and clinicians with innovative diagnostics, Avitia aims to reduce healthcare costs and enhance patient access to personalized cancer treatments, thereby improving overall patient outcomes.
How much funding has Avitia raised?
Avitia has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2025): $5M with participation from PacBridge Partners
Key Investors in Avitia
PacBridge Partners
PacBridge Partners is an investment firm that provides early stage and growth capital, with a focus on disruptive technologies and scalable business models across sectors including life sciences. They offer strategic advice and support to their portfolio companies, investing globally with an emphasis on Asia and North America.
What's next for Avitia?
The recent major strategic investment positions Avitia for accelerated growth and market penetration. With a focus on enterprise-level funding, the company is likely to scale its operations, expand its research and development capabilities, and broaden its commercial reach. This capital will be instrumental in further refining its diagnostic technologies and solidifying its presence in the competitive oncology market, driving forward the adoption of personalized medicine.
See full Avitia company page
